BBA
RNTX

Baker Bros. Advisors’s Rein Therapeutics RNTX Stock Holding History

Baker Bros. Advisors’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-102,000
Closed -$1.47M – 110
2019
Q2 		$1.47M Buy
+102,000
New +$2.68M 0.01% 90

Other funds holding RNTX

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Baker Bros. Advisors's RNTX Position: Q3 2019 in Review

Baker Bros. Advisors sold out of Rein Therapeutics (RNTX) in Q3 2019, closing a stake of 102,000 shares — an estimated $1.47M sold.

Baker Bros. Advisors first reported a position in RNTX in Q2 2019 and held it in 1 quarter. The position peaked at $1.47M in Q2 2019. 22 funds tracked by Wall St. Rank hold RNTX as of Q3 2019.

  • Baker Bros. Advisors reported no remaining Rein Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Baker Bros. Advisors sold 102,000 Rein Therapeutics shares in Q3 2019, an estimated $1.47M.
  • Baker Bros. Advisors first reported a position in Rein Therapeutics in Q2 2019 and held it in 1 quarter.
  • Baker Bros. Advisors's Rein Therapeutics position peaked at $1.47M in Q2 2019.
  • 22 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2019.

Based on Baker Bros. Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.